Through this evaluation, we analyzed the effectiveness of DSCs in improving CGM and insulin pump utilization and overall therapeutic outcomes among underserved adults with T1D and insulin-requiring T2D. This evidence concerns the gene INS and type 2 diabetes mellitus.